glp-1 and gastroparesis New data links agonists for weight loss with higher risk for pancreatitis, GI events Gastroparesis With the Initiation of

And when people tell me they feel stuck with their weight, I always say the same thing:It s never too late to take your health back.

Nutrition lead magnet

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Learn how GLP-1 medications affect hunger, fullness, blood sugar, and weight loss, and why they are more than simple appetite suppressants.